Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Gyre Therapeutics (NASDAQ:GYRE) Shares Slip: What's Pressuring GYRE and What Comes Next?

● Gyre Therapeutics is a biopharmaceutical company built around anti-fibrotic therapeutics, and it reached its current form after a corporate combination that gave a U.S.-listed shell exposure to an established Chinese pharmaceutical operation.

Nitish Kishor | 10 September 2026

Halberd Corp (OTC: HALB) Falls Sharply: Is This a Reset or a Deeper Warning Sign?

Penny stocks rarely tell a clean story, and Halberd Corporation (OTC: HALB) is a case study in why. The shares change hands at a fraction of a cent on the OTC market, so a single-session move of a few percentage points translates into a …

Nitish Kishor | 10 September 2026

Cue Health (OTC:HLTHQ) Went From NYSE Fanfare to Sub-Penny Silence

Cue Health Inc (OTC:HLTHQ) was once a celebrated pandemic-era diagnostics story, a San Diego company whose portable molecular test brought lab-grade COVID-19 detection into the home. Today the shares trade for about a millionth of a dollar on the over-the-counter market under a ticker …

Nitish Kishor | 10 September 2026

Werewolf Therapeutics, Inc (NASDAQ:HOWL) Turns Lower: Why Investors Are Reassessing the Stock

● Based in Waltham, Massachusetts, Werewolf Therapeutics is a clinical-stage biotechnology company built around its PREDATOR platform, which engineers conditionally activated INDUKINE molecules designed to release potent immune-stimulating cytokines preferentially within the tumor microenvironment.

Nitish Kishor | 10 September 2026

Hard To Treat Diseases (OTC:HTDS): An Evocative Name Attached to a 2009 Filing and Nothing Since

An evocative name and a ticker at a hundred-thousandth of a cent make Hard To Treat Diseases Inc (OTC:HTDS) the kind of listing that turns up on speculative screens but almost nowhere else. The company holds itself out, at least by name, in the …

Nitish Kishor | 10 September 2026

Genelux (NASDAQ:GNLX) Shares Slip: What's Pressuring GNLX and What Comes Next?

● Genelux has spent much of 2026 defined by a single question: can its oncolytic virus reach the finish line of a registrational trial before the cash clock runs out?.

Nitish Kishor | 10 September 2026

Genprex (NASDAQ: GNPX) Shares Slip: What's Pressuring the Stock and What Comes Next?

A 1-for-22 reverse stock split, a Nasdaq compliance fight and aMarket Valueof only a few million dollars frame the current story at Genprex, Inc (NASDAQ: GNPX). The Austin-based gene-therapy developer has spent 2026 defending its listing while pushing cancer and diabetes programs forward. A …

Nitish Kishor | 10 September 2026

Gossamer Bio (NASDAQ:GOSS) Stock: Why It's Under Continued Pressure

Gossamer Bio, Inc (NASDAQ:GOSS) has become one of the more volatile names in the pulmonary-disease space after a pivotal trial stumble reshaped itsInvestmentstory in 2026. The stock now trades far below its former levels, and even modest dollar moves translate into large percentage swings …

Nitish Kishor | 10 September 2026

Grapefruit USA (OTC:GPFT) Stock: What's Behind the Steep Decline as Investors Reassess

A double-digit percentage drop grabs attention, but in Grapefruit USA, Inc. (OTC:GPFT) the more revealing figure is the price itself: a few ten-thousandths of a dollar. At that level, a move of a single tick can read as a 29% plunge while representing almost …

Nitish Kishor | 10 September 2026

GlobeStar Therapeutics' (OTC:GSTC) MS Program Hasn't Had an Update Since Early 2024

GlobeStar Therapeutics Corporation (OTC:GSTC) markets itself as a clinical-stage pharmaceutical company, but the more accurate description is a small, quiet OTC name whose flow of announcements has slowed to a trickle. The company's last widely circulated updates are more than a year old.

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…